Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹35.58 Cr
verified against source
Revenue YoY
281.45%
reported change
EBITDA
₹12.54 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Anlon Healthcare delivered a stellar Q3 FY26 with revenue surging to ₹35.78 Cr (up 281% YoY) and EBITDA margin of 35.06%, driven by higher API and intermediate volumes, operating leverage, and improved product mix. PAT turned positive at ₹5.15 Cr vs a loss last year. Management guided for ~30% revenue CAGR over three years, with FY27 revenue of ₹370-380 Cr (conservative) supported by acquisitions of Epico Organics and Bizotic Life Sciences, which will add combined capacity of 1,400-1,600 MTPA. Key growth drivers include CDMO engagements (three molecules under validation), new API launches (7 in FY27), and expansion into peptides and formulations. Risks include high working capital days (currently ~290 days, target 150-160 by FY27) and execution risk in integrating acquisitions and greenfield capex of ₹100-120 Cr.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects consolidated revenue of ₹370-380 Cr for FY27, driven by existing operations and acquisitions, with potential upside.
- Company targets approximately 30% revenue CAGR over the next three years, supported by capacity expansion and new product launches.
- Consolidated EBITDA margin expected to be 32-33% going forward, with Enlon at 35%+ and Epico at ~30%.
- Company plans ₹100-120 Cr capex for greenfield expansion, funded by internal accruals (₹40-50 Cr) and bank debt (₹50-60 Cr), to be completed by March 2027.
Risks flagged
- Receivable days are currently ~290 days, posing cash flow risk. Management targets reduction to 150-160 days by FY27, but execution is uncertain.
- Acquisitions of Epico and Bizotic require smooth integration; any delays or operational issues could impact revenue and margin targets.
- ~30-35% revenue from loxoprofen and ketoprofen; any demand shock or regulatory issue in this segment could materially affect results.
- Existing facilities are near full utilization; until greenfield expansion is operational (by March 2027), growth may be constrained.
Key quotes
- We are believing that result would be much better than 370 to 380 CR.
- We are the only Indian manufacturer of loxoprofen and we'll have the first-mover advantage with monopoly in pain management.
- In healthcare segment all the pharma company in India are almost at the same level... everyone is having equal opportunities.
Research modules